April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging BCMA Targeting Bispecifics in Multiple Myeloma
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
Supportive Care Strategies for Patients with MM on Bispecifics Treatment
Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.
Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
Unmet Needs and Future Directions in the Management of Multiple Myeloma
Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.
Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.
Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.
Application of Bispecific Therapy in Clinical Practice
Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
Role of CAR T-cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.
Relapsed/Refractory Multiple Myeloma: Managing Patients on Bispecific Therapy
Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.
Bispecifics in MM: Future Directions in Care
Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.